- Home
- CTW vs ORMP Comparison
CTW vs ORMP Comparison
Compare CTW & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTW | ORMP |
|---|---|---|
| Founded | 2013 | 2002 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.0M | 170.3M |
| IPO Year | 2025 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CTW | ORMP |
|---|---|---|
| Price | $2.71 | $4.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.5K | ★ 169.6K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 6.51% |
| EPS Growth | N/A | ★ 412.50 |
| EPS | N/A | ★ 2.76 |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.41 | ★ $1.74 |
| Revenue Growth | N/A | ★ 49.25 |
| 52 Week Low | $1.10 | $2.09 |
| 52 Week High | $3.14 | $5.19 |
Technical Indicators
Market Signals| Indicator | CTW | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 60.28 | 70.13 |
| Support Level | $2.09 | $3.91 |
| Resistance Level | $3.05 | $5.10 |
| Average True Range (ATR) | 0.22 | 0.20 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 72.13 | 88.46 |
Price Performance
Historical ComparisonAbout CTW CTW Cayman Class A Ordinary Shares
CTW operates as a gaming platform company providing instant access to free-to-play, browser-based games inspired by popular Japanese animation, including "So I'm a Spider, So What? Ruler of the Labyrinth, Arifureta: From Commonplace to World's Strongest - Rebellion Soul", and "Queen's Blade Limit Break". CTW delivers these games through its flagship HTML5 platform, G123.jp.
About ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.